Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 9/20 | 0.44 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 5/20 | 0.39 |
| ▸ | AURKA | O14965 | 1/20 | 0.38 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | LTK | P29376 | 1/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | CLK2 | P49760 | 1/20 | 0.38 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.38 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23872989 | 0.84 | GRN (0.45) | TGFBR1FYNAURKACSF1RRET | |
| SCHEMBL23872992 | 0.82 | AURKA (0.52) | TGFBR1AURKACSF1RRETLTK | |
| SCHEMBL19657302 | 0.81 | TGFBR1 (0.47) | TGFBR1CLK1CREBBPFYN | |
| SCHEMBL15254975 | 0.79 | TNF (0.47) | TGFBR1CLK1CREBBPFYNCDK5 | |
| SCHEMBL23873192 | 0.77 | GAA (0.44) | TGFBR1AURKACSF1RRETLTK | |
| SCHEMBL18352961 | 0.75 | MET (0.33) | TGFBR1 | |
| SCHEMBL22201892 | 0.74 | FYN (0.36) | FYN | |
| SCHEMBL21765953 | 0.74 | IRAK4 (0.50) | TGFBR1CLK1CREBBPIRAK4 | |
| SCHEMBL13050522 | 0.73 | FYN (0.34) | FYNAURKACSF1RRETLTK | |
| SCHEMBL22891212 | 0.73 | HSD11B1 (0.51) | TGFBR1CLK1IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168070-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-12-24 | — | — | US | disclosed |
| US-10696655-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2019-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200399244-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC3 | TGFBR1 1718/4885CLK1 4244/4885CREBBP 7/4885 |
| US-20190152949-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, HDAC1, HDAC11 | TGFBR1 1533/4885CLK1 4243/4885CREBBP 6/4885 |
| US-11168070-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | TGFBR1 1533/4885CLK1 4243/4885CREBBP 6/4885 |
| US-10696655-B2 | Therapeutic compounds and uses thereof | EP300, HDAC1, HDAC11 | TGFBR1 1533/4885CLK1 4243/4885CREBBP 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.